Interestingly, there is a diagnostic trial recruiting IPF patients to validate the safety, tolerability, kinetics, and repeatability of an LPAR1 PET ligand 18F-BMS-986327 [130]. Here, LPAR1 is linked to idiopathic pulmonary fibrosis.